Clinical Trial Update: ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

This clinical trial is evaluating ALK tyrosine kinase inhibitors in ALK-rearranged advanced squamous cell carcinoma (a form of non-small cell lung cancer) and i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• ALK Tyrosine Kinase Inhibitor (class) (ALK inhibitor)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING